CG Oncology (NASDAQ:CGON) Earns Buy Rating from HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 106.78% from the stock’s current price.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $75.00 price target on shares of CG Oncology in a research report on Thursday. Morgan Stanley assumed coverage on CG Oncology in a report on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group assumed coverage on CG Oncology in a report on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price objective for the company.

CG Oncology Stock Down 8.2 %

Shares of CGON stock opened at $36.27 on Monday. CG Oncology has a 1 year low of $28.55 and a 1 year high of $50.23. The stock’s fifty day simple moving average is $39.63.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CG Oncology stock. Capstone Investment Advisors LLC bought a new position in CG Oncology, Inc. (NASDAQ:CGON) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,354 shares of the company’s stock, valued at approximately $806,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.